QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:RDNTRadNet Stock Price, Forecast & News

$17.52
+0.17 (+0.98 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.25
Now: $17.52
$17.95
50-Day Range
$14.54
MA: $15.86
$17.71
52-Week Range
$5.81
Now: $17.52
$23.45
Volume331,900 shs
Average Volume404,559 shs
Market Capitalization$888.18 million
P/E Ratio438.11
Dividend YieldN/A
Beta1.66
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Read More
RadNet logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDNT
CUSIPN/A
Phone310-478-7808

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.15 billion
Cash Flow$3.27 per share
Book Value$4.63 per share

Profitability

Net Income$14.76 million

Miscellaneous

Employees8,498
Market Cap$888.18 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$17.52
+0.17 (+0.98 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











RadNet (NASDAQ:RDNT) Frequently Asked Questions

How has RadNet's stock price been impacted by COVID-19?

RadNet's stock was trading at $17.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RDNT shares have increased by 1.7% and is now trading at $17.52.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of RadNet?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for RadNet
.

When is RadNet's next earnings date?

RadNet is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for RadNet
.

How were RadNet's earnings last quarter?

RadNet Inc. (NASDAQ:RDNT) released its quarterly earnings data on Monday, August, 10th. The medical research company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.28. The medical research company had revenue of $190.60 million for the quarter, compared to analyst estimates of $190.58 million. RadNet had a net margin of 0.18% and a return on equity of 1.56%. The business's revenue for the quarter was down 34.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.12 EPS.
View RadNet's earnings history
.

What price target have analysts set for RDNT?

2 analysts have issued twelve-month target prices for RadNet's shares. Their forecasts range from $22.00 to $23.00. On average, they expect RadNet's share price to reach $22.50 in the next twelve months. This suggests a possible upside of 28.4% from the stock's current price.
View analysts' price targets for RadNet
.

Has RadNet been receiving favorable news coverage?

News headlines about RDNT stock have been trending somewhat negative on Wednesday, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. RadNet earned a daily sentiment score of -1.2 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about RadNet
.

Are investors shorting RadNet?

RadNet saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 956,100 shares, an increase of 13.5% from the January 31st total of 842,400 shares. Based on an average daily trading volume, of 345,400 shares, the short-interest ratio is currently 2.8 days. Currently, 2.3% of the shares of the company are short sold.
View RadNet's Short Interest
.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Who are RadNet's key executives?

RadNet's management team includes the following people:
  • Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 73)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 48)
  • Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 63)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 58)
  • Mr. Ranjan Jayanathan, Chief Information Officer & GM of Radiology Information Technology Division

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

Who are RadNet's major shareholders?

RadNet's stock is owned by many different institutional and retail investors. Top institutional shareholders include Beck Mack & Oliver LLC (3.82%), Dalton Greiner Hartman Maher & Co. (1.98%), Russell Investments Group Ltd. (0.89%), Bank of New York Mellon Corp (0.87%), Principal Financial Group Inc. (0.64%) and Hennessy Advisors Inc. (0.26%). Company insiders that own RadNet stock include B Kaplan Survivor's Tru Karen, David L Swartz, Jeffrey L Linden, John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock and Norman R Hames.
View institutional ownership trends for RadNet
.

Which major investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Assenagon Asset Management S.A., Prudential Financial Inc., Miracle Mile Advisors LLC, UBS Group AG, Bank of New York Mellon Corp, Alps Advisors Inc., and Bridge City Capital LLC. Company insiders that have sold RadNet company stock in the last year include John V Crues, Mark Stolper, Michael L Md Sherman, and Norman R Hames.
View insider buying and selling activity for RadNet
.

Which major investors are buying RadNet stock?

RDNT stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Beck Mack & Oliver LLC, Jennison Associates LLC, Swiss National Bank, State Board of Administration of Florida Retirement System, Principal Financial Group Inc., Cadence Capital Management LLC, and Comerica Bank.
View insider buying and selling activity for RadNet
.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $17.52.

How big of a company is RadNet?

RadNet has a market capitalization of $888.18 million and generates $1.15 billion in revenue each year. The medical research company earns $14.76 million in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 8,498 workers across the globe.

What is RadNet's official website?

The official website for RadNet is www.radnet.com.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.